What is the mechanism of action of this treatment?

The most common treatments for Non-Hodgkin's Lymphoma (NHL) often involve mechanisms that modulate the immune system and directly target tumor cells. Pleiotropic pathway modulators, such as CC-122, work by affecting multiple signaling pathways that regulate immune responses and tumor cell survival. These agents can enhance the body's immune response against cancer cells while simultaneously inhibiting tumor growth and proliferation. This dual action is particularly important for NHL patients as it offers a comprehensive approach to treatment, potentially leading to better clinical outcomes and prolonged remission periods.

What side effects are associated with this type of intervention?

Common treatments for Non-Hodgkin's Lymphoma (NHL) include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy can cause side effects such as alopecia, nausea, vomiting, fatigue, and increased risk of infections due to bone marrow suppression. Targeted therapies, like those affecting the hedgehog signaling pathway or fibroblast growth factor receptor inhibitors, can lead to alopecia, hypertension, and gastrointestinal issues. Immunotherapies, including checkpoint inhibitors, may cause immune-related adverse effects such as colitis, dermatitis, and endocrinopathies. Treatments similar to CC-122, which modulate the immune system and exhibit anti-tumor activity, may share these side effects, particularly immune-related toxicities and gastrointestinal disturbances.

What prior FDA approvals exist?

FDA-approved treatments for Non-Hodgkin's Lymphoma that are similar to CC-122, which modulates the immune system and has anti-tumor activity, include lenalidomide and rituximab. Lenalidomide, an immunomodulatory drug, has shown efficacy in relapsed or refractory NHL. Rituximab, a monoclonal antibody targeting CD20, is widely used in various NHL subtypes and works by enhancing the immune system's ability to destroy cancer cells. These treatments, like CC-122, leverage the body's immune response to combat lymphoma.

What other types of research exist?

Promising novel alternatives to CC-122 for Non-Hodgkin's Lymphoma patients include: 1) Evinacumab, an ANGPTL3 monoclonal antibody, which has shown significant LDL-C reduction and potential benefits in lipid metabolism; 2) Immune checkpoint inhibitors like pembrolizumab and nivolumab, which have demonstrated efficacy in various cancers including NHL by enhancing the immune response against tumor cells; 3) Imetelstat, an investigational antisense oligonucleotide targeting telomerase, which has shown partial and complete responses in myelofibrosis and may have potential in NHL. These alternatives are based on their mechanisms of action and recent clinical trial results.

← Back to Search

Immunomodulatory Agent

CC-122 for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial provides CC-122 treatment to participants who have benefited from it in previous trials for a long period. The study aims to monitor their safety and how well they tolerate the medication. CC-122 works by enhancing the immune system to fight diseases.

Who is the study for?

This trial is for people with Non-Hodgkin's Lymphoma who are already participating in other CC-122 studies and benefiting from the treatment without experiencing disease progression or reasons to stop as per previous study rules.

What is being tested?

The trial continues providing a drug called CC-122 to participants from earlier trials. It aims to understand long-term safety and how well patients tolerate continued use of this medication over time.

What are the potential side effects?

While specific side effects aren't listed, they will monitor how the body handles CC-122, which may include tracking any adverse reactions or discomforts that arise during extended treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: CC-122 and DexamethasoneExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CC-122

2015

Completed Phase 2

~660

Dexamethasone

2007

Completed Phase 4

~2650

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Non-Hodgkin's Lymphoma (NHL) often involve mechanisms that modulate the immune system and directly target tumor cells. Pleiotropic pathway modulators, such as CC-122, work by affecting multiple signaling pathways that regulate immune responses and tumor cell survival. These agents can enhance the body's immune response against cancer cells while simultaneously inhibiting tumor growth and proliferation. This dual action is particularly important for NHL patients as it offers a comprehensive approach to treatment, potentially leading to better clinical outcomes and prolonged remission periods.